Navigation Links
All HIV Patients Should Take Meds Early On, Experts Now Say
Date:7/23/2012

MONDAY, July 23 (HealthDay News) -- A new report recommends that physicians begin treating all HIV-positive adults with antiretroviral drugs instead of waiting, at least in countries where the therapy is easily accessible.

All HIV-positive patients should take the drugs, even if blood tests reveal that their immune system is healthy, according to the revised guidelines, which were presented Sunday at the International AIDS Conference in Washington D.C., and published in the July 25 issue of the Journal of the American Medical Association.

Over the last 25 years, antiretroviral drugs have become stronger, easier to tolerate and simpler to take, the authors of the report explained. "New trial data and drug regimens that have become available in the last two years warrant an update to guidelines for antiretroviral therapy in HIV-infected adults in resource-rich settings," Dr. Melanie Thompson and her 2012 International Antiviral Society-USA Panel colleagues said in the report.

While medications don't rid the body of HIV -- the virus that causes AIDS -- they can prevent the virus from replicating and have allowed millions of people to live for years with a greatly reduced threat of developing AIDS, experts have noted.

However, not every person infected with HIV takes the medications. In some cases, doctors prefer to wait until a patient's immune system begins to show signs that the virus is becoming stronger.

The reasons why doctors sometimes wait to prescribe antiretroviral medications may be because the drugs can cause side effects, and there's also the challenge that patients must keep taking them or take the risk that the virus will rebound.

Commenting on the report, Rowena Johnston, director of research with the Foundation for AIDS Research in New York City, explained, "We can't lose sight of the fact that this is a big commitment. Once you start, you can't stop."

The report recommends that initial treatment include two nucleoside reverse transcriptase inhibitors (tenofovir/emtricitabine [brand name Truvada] or abacavir/lamivudine [known as ABC/3TC]) plus a non-nucleoside reverse transcriptase inhibitor (efavirenz [Sustiva]), a ritonavir-boosted protease inhibitor (atazanavir [Reyataz] or darunavir [Prezista], or an integrase strand transfer inhibitor (raltegravir [Isentress]).

The new guidelines are a sign of a "turning point" for HIV drugs, Johnston said. These medications are now being considered not only as a treatment but as a prevention tool because those who take them are less likely to infect other people, she noted. "The scientific community really recognizes how valuable they could be to prevent transmission," she said.

There are challenges, though, Johnston pointed out. One obstacle is money to pay for the drugs, even in rich countries such as the United States. There's also the matter of getting people to be tested in the first place and then to seek and retain medical care if they learn they are HIV-positive, she said.

More information

The U.S. National Institute of Allergy and Infectious Diseases has more about HIV and AIDS.

-- Randy Dotinga

SOURCES: Rowena Johnston, Ph.D., director, research, Foundation for AIDS Research, New York City; July 25, 2012, Journal of the American Medical Association


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Young Cancer Patients Often Lack Support: Study
2. Not All HIV Patients in U.S. Show Same Characteristics: Study
3. Increased cardiovascular risk in HIV-infected patients may relate to arterial inflammation
4. Among new HIV treatment recommendations, all adult patients should be offered antiretroviral therapy
5. Doctors Tend to Share Patients With Similar Colleagues
6. Many Medicaid Patients Skip Drugs That Could Prevent Heart Trouble
7. Meta-analysis: Interventions improve depression in cancer patients
8. CPAP treatment effective in patients with milder OSA and daytime sleepiness
9. Helping Alzheimers patients stay independent
10. New targeting technology improves outcomes for patients with atrial fibrillation
11. A stronger doctor-patient relationship for the costliest patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
All HIV Patients Should Take Meds Early On, Experts Now Say
(Date:9/3/2020)... ... September 03, 2020 , ... ... will be held Wednesday, April 7, to Saturday, April 10, 2021, at Wynn ... Spa Show is a national trade show for non-invasive medical aesthetic practices that ...
(Date:9/1/2020)... SEATTLE (PRWEB) , ... September 01, 2020 , ... ... that it has completed $3 million convertible note financing, which will be used ... , With the funds from this financing, the company will continue to expand ...
(Date:8/31/2020)... ... 31, 2020 , ... The Lymphoma Research Foundation (LRF) ... research and serving the lymphoma community through a comprehensive series of education programs, ... Cancer Awareness Month (BCAM) and its international Light it Red for Lymphoma ...
(Date:8/31/2020)... ... August 31, 2020 , ... Colorado State University Global (CSU ... affordable online education – is proud to announce its new master’s degree in ... its kind in the nation, the 60-credit hour program is designed to provide ...
(Date:8/31/2020)... PASADENA, Calif. (PRWEB) , ... August 31, 2020 ... ... and leadership experience working, both directly with persons with autism and other developmental ... clinical expertise includes early intervention, parent education, adolescents with autism, school consultation, and ...
Breaking Medicine News(10 mins):
(Date:9/3/2020)... ... 03, 2020 , ... Q&J Face Masks announced today that ... and engineering lab, conducted tests on Q&J’s personal face mask that indicated the ... other masks. Q&J face masks have both mechanical filtering and electrostatic filtering which ...
(Date:9/2/2020)... ... September 02, 2020 , ... Rigaku Analytical Devices , ... among industry professionals about successes and challenges of making changes to their organizations’ ... and will take place on October 15, 2020 at 10:00am PDT / ...
(Date:9/1/2020)... ... September 01, 2020 , ... Agilent, ... the Agilent Science and Technology Virtual Symposium 2020 (ASTVS 2020) on ... open a suite of Live webinars and Networking sessions, with a vast array ...
Breaking Medicine Technology: